By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Viralytics Ltd 

66 Hunter Street, Suite 305, Level 3

  Sydney  2000  Australia
Phone: 61-2-8889-3671 Fax: 61-2-8068-6038



Company News
Viralytics Ltd (VLA.AX) Completes $28 Million Placement -- SPP To Follow 12/14/2015 11:13:52 AM
Viralytics Ltd (VLA.AX) Completes $28 Million Placement -- SPP To Follow 12/14/2015 6:42:49 AM
Viralytics Ltd (VLA.AX) Release: Positive CAVATAKTM Clinical Data Presented At 2015 Society For Immunotherapy Of Cancer (SITC) Meeting 11/9/2015 12:50:21 PM
Viralytics Ltd (VLA.AX) And Merck & Co. (MRK), Kenilworth, New Jersey, U.S.A. To Collaborate On Combination Clinical Trial Of CAVATAK And KEYTRUDA In Lung And Bladder Cancer 11/6/2015 6:34:59 AM
Viralytics Ltd (VLA.AX) Initiates Clinical Trial Of CAVATAK In Combination With PD-1 Blocker Keytruda 9/28/2015 9:57:37 AM
Viralytics Ltd (VLA.AX) Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress 9/28/2015 9:55:32 AM
Viralytics Ltd (VLA.AX) Presents CALM And STORM Clinical Trial Results At Oncolytic Virus Therapeutics Conference 6/17/2015 9:07:06 AM
Viralytics Ltd (VLA.AX) Release; CAVATAK Presentations At Oncolytic Virus Therapeutics Conference Reinforce Potential In Bladder Cancer And Melanoma 6/16/2015 9:24:13 AM
Viralytics Ltd (VLA.AX) Reports Positive Final Results From CAVATAKTM Phase 2 Melanoma Trial 6/2/2015 9:17:26 AM
Viralytics Ltd (VLA.AX) To Present Final Clinical Data From CALM Trial At ASCO Annual Meeting 2015 5/13/2015 11:51:07 AM